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Abstract
Background: Claudication secondary to peripheral artery disease (PAD) is associated with substantial functional
impairment. Phosphodiesterase (PDE) inhibitors have been shown to increase walking performance in these patients. K-
134 is a selective PDE 3 inhibitor being developed as a potential treatment for claudication. The use of K-134, as with
other PDE 3 inhibitors, in patients with PAD raises important safety and tolerability concerns, including the induction of
cardiac ischemia, tachycardia, and hypotension. We describe the design, oversight, and implementation of an adaptive,
phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication.
Methods: The study design was a double-blind, multi-dose (25 mg, 50 mg, and 100 mg of K-134), randomized trial
with both placebo and active comparator arms conducted in the United States and Russia. The primary objective
of the study was to compare the highest tolerable dose of K-134 versus placebo using peak walking time after 26
weeks of therapy as the primary outcome. Study visits with intensive safety assessments were included early in the
study period to provide data for adaptive decision making. The trial used an adaptive, dose-finding strategy to
efficiently identify the highest dose(s) most likely to be safe and well tolerated, based on the side effect profiles
observed within the trial, so that less promising doses could be abandoned. Protocol specified criteria for safety
and tolerability endpoints were used and modeled prior to the adaptive decision making. The maximum target
sample size was 85 subjects in each of the retained treatment arms.
Results: When 199 subjects had been randomized and 28-day data were available from 143, the Data Monitoring
Committee (DMC) recommended termination of the lowest dose (25 mg) treatment arm. Safety evaluations performed
during 14- and 28-day visits which included in-clinic dosing and assessments at peak drug concentrations provided
core data for the DMC review. At the time of review, no subject in any of the five treatment arms (placebo, three K-134-
containing arms, and cilostazol) had met pre-specified definitions for resting tachycardia or ischemic changes on
exercise ECG. If, instead of dropping the 25-mg K-134 treatment arm, all arms had been continued to full enrollment,
then approximately 43 additional research subjects would have been required to complete the trial.
Conclusions: In this phase II, dose-finding trial of K-134 in the treatment of stable intermittent claudication, no
concerning safety signals were seen at interim analysis, allowing the discontinuation of the lowest-dose-containing
arm and the retention of the two highest-dose-containing arms. The adaptive design facilitated safe and efficient
evaluation of K-134 in this high-risk cardiovascular population.
Trial registration: ClinicalTrials.gov: NCT00783081
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Peripheral artery disease (PAD) is a common manifesta-
tion of systemic atherosclerotic disease, and is associated
with both coronary and carotid arterial disease leading
to increased risk of myocardial infarction, stroke and
death [1,2]. Medical treatment of PAD includes manage-
ment of cardiovascular risk factors and the use of anti-
platelet agents to reduce the risk of myocardial
infarction and ischemic stroke.
Approximately one-third of patients with PAD suffer
from claudication, typified by pain in one or both legs
that is brought on by walking and relieved by rest [3].
Claudication is associated with decreased functional
capacity, impairment of activities of daily living, and
reduced quality of life. Currently, cilostazol is the only
guideline-recommended pharmacologic agent approved
in the United States for the treatment of claudication
[4]. Cilostazol is a phosphodiesterase (PDE) 3 inhibitor
with vasodilatory and antiplatelet activity. Treatment
with cilostazol is associated with both an increase in
peak treadmill performance and an improvement in
quality of life [5]. Another PDE 3 inhibitor, NM-702,
has been evaluated in a phase II study with positive
results [6]. However, treatment with PDE 3 inhibitors
can cause adverse effects; cilostazol can cause ortho-
static hypotension, tachycardia, palpitations and head-
ache. In patients with underlying vascular disease, the
induction of hypotension and tachycardia raise con-
cerns for induction of ischemic events. Perhaps related
to this, the PDE 3 inhibitor milrinone has been asso-
ciated with increased mortality in patients with severe
heart failure [7].
K-134 is a selective PDE 3 inhibitor that in Phase I
trials involving healthy volunteers has the expected
vasodilatory effects and appears to have more pro-
nounced antiplatelet effects than cilostazol. Although
PDE 3 inhibitors have been used successfully to treat
claudication, this class of agents raises important safety
concerns when used in a population at high risk for
underlying cardiovascular disease. Thus, a clinical trial
supporting early drug development of a PDE 3 inhibitor,
especially in patients suffering from claudication, must
be designed to assess potential safety concerns while
minimizing risks to study participants. The risk-benefit
analysis is made more difficult, however, by the fact that
some adverse effects (e.g., hemodynamic changes) are
likely to occur quite early in treatment, while the benefi-
cial effect may require six months or longer to fully
develop. Additionally, safety and tolerability data from
healthy subjects may not be predictive of effects in
patients with claudication.
We describe the novel design, oversight, and adaptive
decision process associated with a phase II, dose-finding
trial evaluating K-134 for the treatment of stable, inter-
mittent claudication. Because of limited prior clinical
experience with K-134 in the target population, the ethi-
cal imperative to rapidly eliminate from further use any
treatments or dosing strategies that are unsafe or poorly
tolerated, and the limited availability of patients with
stable intermittent claudication for recruitment, an
adaptive approach was used to rapidly identify and
restrict randomization to the maximum safe and well-
tolerated doses of K-134 in the target population [8].
The purpose of this article is to illustrate the capability
of a customized adaptive clinical trial design to use
active and ongoing assessment of safety and tolerability
to better inform interim decision making regarding the
termination of both specific dosing strategies and,
potentially, the clinical trial itself [8,9]. The primary
results of the clinical trial will be published separately.
Methods
Study Design and Setting
The study design was a parallel treatment, multi-dose,
randomized trial with both placebo and active compara-
tor arms. A Steering Committee oversaw the design,
conduct of the trial, and dataa n a l y s i s .B yC h a r t e rt h e
trial’s Data Monitoring Committee reported to the
Steering Committee. Kowa Research Institute (KRI)
maintained overall regulatory responsibility for the study
and contracted with an academic research organization
to implement the trial. The trial incorporated the
planned, adaptive elimination of one or more treatment
arms based on predefined safety and tolerability end-
points. The adaptive aspects of the trial design were
developed collaboratively by the trial’s Steering Commit-
tee, Kowa Research Institute, and the Data Monitoring
Committee. The voting statistician member of the Data
Monitoring Committee conducted simulations of the
adaptive design and performed the required dose-
response modeling during conduct of the trial. The
study was conducted in 25 sites in the United States
and 23 sites in Russia.
Patient Population
The eligible patient population included patients ages
40 years or greater with a diagnosis of intermittent clau-
dication confirmed by both history and one of the fol-
lowing: (1) a resting ankle brachial index (ABI) ≤ 0.90 at
screening; (2) a resting ABI ≥ 0.90 and ≤ 1.00 with a
reduction of ≥ 0.20 when measured one minute after
treadmill exercise; or (3) an ankle brachial index > 0.90
and a resting toe brachial index < 0.70 in diabetic
patients. The symptoms of claudication were required to
be stable for three months prior to screening and the
subject must have demonstrated a highest peak walking
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excluded if they exhibited signs or symptoms of critical
leg ischemia, had undergone recent revascularization
procedures or coronary artery bypass grafting, or had
unstable cardiovascular disease, a history of congestive
heart failure or the presence of congestive heart failure
as defined by the modified Framingham criteria. Addi-
tional exclusion criteria were defined to avoid enrolling
patients at additional risk from participation or in
whom claudication-limited treadmill performance could
not be ascertained.
In the United States, the trial was approved by a cen-
tral Institutional Review Board (IRB), Western IRB
(WIRB) in Olympia, Washington, and by individual
local IRBs according to the requirements of each site.
In Russia, the trial was approved by the Russian
National Ethics Committee and institutional ethics
committees (IECs) as required by each site. Voluntary,
written informed consent was obtained from each
research subject prior to performing any study-related
procedures.
Treatment Arms
Patients were randomized t oo n eo ff i v et r e a t m e n t
arms: (1) placebo; (2) K-134 25 mg twice daily
(referred to as the 25 mg arm); (3) K-134 25 mg twice
daily with a forced titration to 50 mg twice daily after
two weeks (referred to as the 50 mg arm); (4) K-134
50 mg twice daily with a forced titration to 100 mg
twice daily (referred to as the 100 mg arm); or (5)
cilostazol 100 mg twice daily. All drugs were adminis-
tered orally. The purpose of the forced titration dosing
strategy, used in the two higher-dose K-134 arms, was
to allow subjects time to acclimate to the pharmacolo-
gic effects of K-134 and maximize tolerability. This
strategy allowed a safety assessment at the day-14 visit,
prior to up-titration. Patients were randomized, after
the successful completion of prerequisite baseline eva-
luation, using an interactive voice recognition system
(IVRS) as is typical for large, multicenter, international
clinical trials.
Trial Objectives
The primary objective of the study was to compare the
highest safe and tolerable dose of K-134 versus placebo
using peak walking time after 26 weeks of therapy as
the primary endpoint. The primary outcome was mea-
sured as a change from baseline in peak walking time,
utilizing a graded exercise treadmill test with a modified
Gardner protocol. Secondary objectives included evalu-
ating the safety and efficacy of different doses of K-134
versus placebo at 26 weeks, comparing the safety and
efficacy of K-134 versus cilostazol, and exploring the
pharmacodynamics of K-134.
Safety and Tolerability Endpoints for Adaptive Decision
Making
The trial used an adaptive, dose-finding strategy to
efficiently identify the dose(s) most likely to be safe and
well tolerated, based on the side effect profiles observed
within the trial, so that less promising doses could be
rapidly abandoned and study resources could be utilized
most efficiently. The target sample size for each retained
study arm was 85 subjects, with the final sample size
depending on the number of retained arms.
The target sample size of 85 in each of the study arms
was determined based on prospective power calculations
under a variety of projected effect sizes, assuming a
single pairwise comparison of the highest retained dose
of K-134 to placebo (80% power if K-134 increased peak
walking time by 40% and 42% power if peak walking
time increased by 30%, assuming 20% discontinuation
rate). Additionally, the number was felt to be adequate
to ensure adequate information on the dose ranging of
K-134.
The goal of the adaptive design was to drop from the
trial, as quickly as possible, any K-134 dosing regimens
that had unacceptable rates of adverse effects or were
poorly tolerated. If all arms were safe and well tolerated
then the lowest dose was to be dropped. Given the
absence of previous experience with K-134 in the PAD
population and the known pharmacodynamics of the
class, the protocol incorporated safety check points at
day 14 (prior to the dose increase in the 50 mg and 100
mg K-134 arms), and at day 28 after two weeks of treat-
ment with the assigned dose. Although, atypical for
claudication studies, the 28 day visit included a peak
treadmill test conducted at peak drug concentrations
with ECG monitoring to allow a comprehensive safety
assessment. Two safety endpoints and one tolerability
endpoint were assessed at these visits and used to
inform the adaptive design, namely: (1) the development
of a resting tachycardia, defined as any heart rate greater
than 120 bpm or greater than 110 bpm on two consecu-
tive assessments 15 minutes apart, measured at time
points estimated to correspond to maximal serum drug
concentration, occurring either 14 or 28 days after treat-
ment initiation, with the highest acceptable proportion
of patients experiencing this safety endpoint set at 20%;
(2) the development of ECG changes suggestive of
ischemia on maximal treadmill testing at the 28 day
visit, with a maximum tolerable fraction of patients
experiencing this event set at 20%; and (3) the disconti-
nuation of the study medication, for any reason, with
the maximum tolerable limit on this safety endpoint set
at 40%. The first two endpoints, tachycardia and ische-
mia, were considered safety endpoints while the discon-
tinuation of study medication was considered the
tolerability endpoint.
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multiple hemodynamic abnormalities at two weeks and
for resting tachycardia or ECG changes suggestive of
ischemia at four weeks. While the four-week evaluation
was considered the primary safety evaluation, any sub-
ject who experienced resting tachycardia or other hemo-
dynamic changes requiring withdrawal of the study
medication at two weeks would be included in the
group of subjects who had discontinued the medication
when evaluating the tolerability of the study medica-
tions. Further, if the specific reason the study medica-
tion was discontinued at two weeks was resting
tachycardia, then the patient was also considered to
have met the criterion for the resting tachycardia
adverse effect at four weeks. Thus, at the time of the
interim analysis, it was anticipated that there would be
patients whose data from the two-week visit were
known but whose four-week data were not yet available.
This approach was taken to most rapidly identify those
patients experiencing adverse effects of the investiga-
tional medication.
Definition of the Adaptive Design
The first adaptive interim analysis was planned to occur
after 4-week visit data were available from 50 patients,
a tw h i c ht i m ed a t af r o ma p p r o x i m a t e l y1 0s u b j e c t si n
each of the K-134-containing arms would be available. If
deemed necessary by the independent data monitoring
committee (DMC), the protocol specified that a second
adaptive interim analysis could be conducted after
4-week visit data were available from 100 patients, at
which time approximately data from 20 subjects in each
of the K-134-containing arms would be available.
For each adaptive interim analysis, dose-response
models for each of the three safety and tolerability end-
points (resting tachycardia, ECG changes suggestive of
ischemia, and discontinuation of study medication) were
developed. The guideline for dropping of a dose was
based on the 80%, two-tailed confidence interval for the
incidence of each endpoint at each dose, based on these
logistic dose-response models. The use of dose-response
modeling allowed information from all doses, including
placebo, to contribute to the estimates obtained at each
dose. If the 80% confidence interval for the fraction of
patients experiencing the safety or tolerability endpoint
lied completely above the maximum tolerable limit for a
given dose, then that dose and any higher doses were to
be discontinued (Figure 1).
The use of an 80% confidence interval for this purpose
was based on Monte Carlo simulations of thousands of
repetitions of the proposed clinical trial, using a variety
of coverage probabilities, and under a variety of assump-
tions regarding true rates of adverse events (either the
adverse effects of resting tachycardia, ECG changes
suggesting ischemia, or patients discontinuing their
study medication) with the different doses of K-134.
Thus, the 80% coverage probability was not selected
based on a theoretical consideration but, instead, based
on the observation that this approach provided reason-
able assurance of retaining treatment arms with
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Figure 1 Schematic of Adaptive Arm-dropping Strategy.T h i s
figure illustrates the adaptive arm-dropping strategy planned for the
trial, based on the use of logistic dose-response models to integrate
information from the placebo and all K-134 containing arms. Initially,
the trial begins with equal randomization to the placebo, cilostazol,
and the three K-134-containing arms. At each of two planned interim
analyses, occurring when 28-day data are available from either 50 or
100 patients, logistic dose-response models are fit for each of the three
safety and tolerability endpoints (resting tachycardia [denoted HR >
120], signs of ischemia on ECG, and medication discontinuation), using
data from the placebo and K-134-contining arms. If the lower limit of
the 80% confidence interval around the logistic model (the upper and
lower limits are illustrated by dotted lines) exceeds the maximum
tolerable limit of the safety or tolerability endpoint at a particular dose
(excluding placebo), then that arm of the trial is to be discontinued. In
the hypothetical scenario shown in the figure, the ischemia safety
endpoint limit is exceeded (arrow) when N = 50 for the highest (100
mg) dose of K-134 so that arm is discontinued and the four remaining
arms are continued until N = 100. At the second interim analysis,
however, the maximum tolerable rate for resting tachycardia is
exceeded by the lower limit of the 80% confidence interval at both the
50-mg and 100-mg doses (arrows). Since the 100-mg dose was already
discontinued in this hypothetical example at the 50-patient review, the
50-mg dose arm would be discontinued at this point and new
research subjects would be randomized in a balanced manner to one
of the three remaining arms for the remaining duration of the trial.
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provided a high probability of dropping an arm that was
unsafe or poorly tolerated. It is useful to note that the
80% coverage probability is more aggressive in allowing
the termination of arms with potential safety or toler-
ability problems–it results in our requiring less evidence
to drop an arm compared to what would have happened
if we had used 95% confidence intervals.
The overall goal was to retain the two highest-dose
arms with acceptable safety and tolerability event rates,
assuming two such arms existed. However, if both the
50-mg and 100-mg arms were found to have unaccepta-
ble dose-limiting event rates, the trial was to be contin-
ued with only a single K-134-containing arm (the 25-mg
arm). If all three K-134-containing arms were found to
have unacceptable dose-limiting event rates, the DMC
was to recommend early termination of the trial. While
this guideline for the dropping of trial arms was prede-
fined, the DMC was empowered to use judgment and
all available information in implementing the dose arm
stopping guidelines, for example, if some of the informa-
tion was internally inconsistent or additional informa-
tion (e.g., the event rate in the cilostazol arm or
unanticipated adverse events) was deemed relevant.
Results
Meetings of the Independent Data Monitoring
Committee (DMC)
A first, inaugural meeting of the DMC was held on July
1, 2008 and included representatives of the sponsor,
Steering Committee, project support personnel, and
members of the DMC. Background information regard-
ing preclinical and prior clinical experience with K-134
was provided and the rationale for using an adaptive
dose ranging approach was discussed. At this meeting,
the operating characteristics of the planned approach to
treatment arm selection was presented by the statistician
member of the DMC, based on simulation studies con-
ducted by that DMC member (see Additional File 1),
and unanimously judged to be acceptably accurate in
both the dropping of arms with unacceptable safety or
tolerability profiles and in retaining arms with accepta-
ble characteristics. In addition, to discussing logistical
issues, the group reviewed the draft DMC Charter (see
Additional File 2) and approved the adaptive dose find-
ing strategy as presented.
During the second DMC meeting on August 26, 2008,
the DMC reviewed and approved the trial protocol. The
first subject was randomized on December 5, 2008. The
DMC met for a third time on April 21, 2009 by telecon-
ference to conduct a “dry run” for the upcoming interim
analysis meeting, during which a decision regarding
dropping one or more treatment arms would be
considered. During this meeting, issues regarding the
recording, definition, and tabulation of key endpoints
were discussed. For example, clarifying that for subjects
who had completed the 14-day, but not the 28-day visit,
the heart rate measured on day 14 alone could be used
to define the safety endpoint of resting tachycardia.
Although by prior agreement no consideration of termi-
nation of a treatment arm was considered at this meet-
ing, the group reviewed current logistic dose-response
modeling results to ensure the analysis approach was
well understood by the group. At that time, data from
anywhere between 11 and 21 subjects were available for
each of the three safety and tolerability endpoints
(distributed across all five arms).
In prior meetings, the DMC had been informed that
the sponsor was simultaneously conducting a trial of
K-134 in Japan. While it was acknowledged by all that
the patient populations and pharmacokinetics would
likely be different in the Japanese versus the American
and Russian populations, the DMC felt that adverse
event data from the Japanese trial might be helpful in
interpreting the sparse safety data expected to be avail-
able early in the current trial. Based on the rationale that
the DMC should be provided with access to safety and
tolerability information from all reliable sources, the
DMC requested serious adverse event and treatment
assignment information from the ongoing Japanese trial.
The sponsor agreed to this request and provided serious
adverse event and sealed treatment assignment informa-
tion (with language translation) to the DMC chair prior
to the adaptive interim analysis meeting. No sponsor
personnel were unblinded to treatment assignment.
Interim Analysis Results and Adaptive Decision Making
At the fourth meeting of the DMC, held on July 10,
2009, a total of 199 subjects had been randomized and
28-day visit data were available from 143. A rapidly-
increasing rate of subject enrollment and scheduling
constraints resulted in data from a larger sample being
available at the time of the first interim analysis than
originally planned. Thus, at the time of this interim ana-
lysis, 28-day visit data were available from a larger num-
ber of subjects than had been planned, even for the
second interim analysis. In open session, the DMC
Chair reviewed the statistical guidelines for the planned
arm-dropping adaptation and informed the group that
the serious adverse event data from the concurrent Japa-
nese trial were available for closed review by the DMC if
deemed necessary. In closed session, the DMC discussed
details of the closed reports, focusing on data quality in
the reporting of the corrected QT interval (QTc)
obtained from ECGs, and were informed that the statis-
tical programs used to create the adaptive endpoint
dose-response analyses had been independently
validated by the unblinded statistician assigned to the
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data from the study and identified no substantial con-
cerns. Based on this observation, the Committee voted
unanimously not to review the sealed Japanese serious
adverse event data that had been provided, based on
knowledge of the total number of serious adverse events
that had occurred in the Japanese trial and the rationale
that no reasonably plausible pattern in serious adverse
events in the Japanese trial would warrant an alteration
in the current trial.
The observed dose-response models for each of the
three safety and tolerability endpoints were then consid-
ered (Table 1). No subject in any of the five treatment
arms (placebo, three K-134-containing arms, and cilosta-
zol) demonstrated resting tachycardia or ischemic
changes on ECG meeting the pre-specified criteria. As
mentioned above, the number of subjects available was
greater than the originally-planned number. For
example, a total of 115 subjects were included in the
dose-response model for tachycardia, with 85 receiving
K-134, although some of these had only 2-week data
available. However, due to limitations in data availability,
only 63 subjects were included in the model for
ischemic changes, with 43 receiving K-134. Three of the
25 (12%) subjects receiving 100 mg of K-134 had dis-
continued their medication; 1 of 32 (3%) subjects receiv-
ing 50 mg and 1 of 28 subjects (4%) receiving 25 mg
had discontinued. No subjects (0 of 32 [0%]) receiving
placebo had discontinued. Since the observed disconti-
nuation rate (12%) at the highest dose was still well
below the maximum allowed rate of 40%, there was no
suggestion of unanticipated tolerability concerns in any
of the K-134-containing arms. Based on the lack of any
concerning safety or tolerability endpoint data, the
DMC recommended the termination of the 25-mg arm,
applying the predefined strategy of retaining the two
highest safe and tolerable K-134-containing arms. This
recommendation was presented to and accepted by the
trial’s Steering Committee immediately following the
closed DMC meeting and subsequently implemented by
the sponsor.
Implementation of the Adaptation
To implement the adaptive elimination of the 25-mg
dose arm, the sponsor and contractor supporting the
trial rapidly took steps: (1) to modify the trial’s randomi-
zation system so no new subjects would be assigned to
the 25-mg arm; (2) to obtain a listing of all subjects
previously randomized to the 25-mg arm while not
compromising the blinding of other subjects; (3) to
notify clinical study sites which of their patients should
be scheduled for study termination; (4) to communicate
to each site that this termination was based on the pre-
specified adaptive design but not to identify which treat-
ment arm was to be discontinued; and (5) to revise the
total planned sample size for the trial, allowing for the
subjects being discontinued because of prior allocation
to the 25-mg K-134 arm. These steps were completed
within 3 days of the July 10 meeting. The communica-
tion sent to each clinical trial investigator emphasized
that the discontinuation of subjects was part of the pre-
specified adaptive design of the study and that the com-
munication should be shared with the Institutional
Review Board (IRB) or Institutional Ethics Committee
Table 1 Safety and Tolerability Endpoints at Time of Interim Analysis on July 10, 2009*
Endpoint Trial Arm Observed Rate Model-based Rate (80% CI)
Placebo 0 of 30 (0%) 0.0 (—, —)
25 mg K-134 0 of 29 (0%) 0.0 (—, —)
Resting Tachycardia 50 mg K-134 0 of 30 (0%) 0.0 (—, —)
100 mg K-134 0 of 26 (0%) 0.0 (—, —)
Cilostazol 0 of 28 (0%)
Placebo 0 of 20 (0%) 0.0 (—, —)
25 mg K-134 0 of 14 (0%) 0.0 (—, —)
Ischemic ECG Changes 50 mg K-134 0 of 19 (0%) 0.0 (—, —)
100 mg K-134 0 of 10 (0%) 0.0 (—, —)
Cilostazol 0 of 15 (0%)
Placebo 0 of 32 (0%) 0.009 (0.002, 0.038)
25 mg K-134 1 of 28 (4%) 0.018 (0.004, 0.072)
Discontinuation 50 mg K-134 1 of 32 (3%) 0.035 (0.009, 0.13)
100 mg K-134 3 of 25 (12%) 0.12 (0.032, 0.37)
Cilostazol 1 of 27 (0%)
*See text for definitions of safety and tolerability endpoints.
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arm was being discontinued was known only to the
Steering Committee and key personnel at the sponsor,
and was not communicated to site investigators. Lastly,
the subjects’ study physicians were instructed to conduct
a final evaluation and the patients were transferred to
standard care according to their personal physicians’
preferences.
In follow up to the July 10, 2009 meeting of the DMC,
the sponsor identified a number of factors that contribu-
ted to the missing data at the time of review regarding
ST segment depression and related ECG outcomes at
d a y2 8 .T h ea v a i l a b i l i t yo fd a t ae l e m e n t sa tt h et i m eo f
the formal interim analysis was influenced by multiple
factors, including: (1) the timing of data collection for
each element; (2) the time delay associated with central
laboratory ECG reading; and (3) time required for the
submission of CRFs and the monitoring of data from
each site. The larger quantity of missing ECG data was
largely the result of the time required for receipt and
central over-reading of ECGs.
A repeat analysis of the three safety and tolerability
endpoints with a more complete data set was conducted
on September 23, 2009 demonstrating that none of 130
(0%) subjects receiving K-134 demonstrated tachycardia
at either 14- or 28-days of treatment and none of 96
subjects (0%) receiving K-134 had exhibited ischemic
ECG changes at 28 days (Table 2). The overall disconti-
nuation rates were verified to be consistent with those
seen in July. Although the DMC’s adaptation recom-
mendation had been provided, accepted, and implemen-
ted, the DMC continued to receive and review safety
and tolerability endpoint dose-response models
periodically.
On November 24, 2009, the DMC met a fifth time to
c o n d u c tad e t a i l e dr e v i e wo fs e r i o u sa d v e r s ee v e n t s
(SAEs) in the trial. This review was conducted in an
unblinded manner in closed session. It was noted that a
substantial fraction of all SAEs (35% or 6 of 17) had
occurred in the placebo arm. Further, there was no
apparent difference in the incidence of SAEs by country
or by subject age.
In consultation with the trial’s Steering Committee,
the DMC agreed that further DMC oversight should be
focused on the review of SAE and adverse event (AE)
experience in the trial. The DMC met a sixth time on
February 3, 2010 to review both AE and SAE informa-
tion. The DMC noted potential dose-response relation-
ships for K-134 with the occurrence of palpitations,
gastrointestinal disorder (e.g., diarrhea, nausea) and
edema. Tachycardia and hypovolemia were specifically
noted to be absent from AE reports. At the DMC meet-
ings of July 10, 2009, November 24, 2009, and February
3, 2010, the DMC reviewed detailed tabulations and
graphical presentations of hemodynamic and ECG data.
No concerning patterns were observed, although the
changes expected in the cilostazol arm were noted. The
study was successfully completed with last patient visit
occurring July 7, 2010 and database lock occurring July
28, 2010. All contents of this manuscript were embar-
goed within the DMC until after database lock had been
confirmed.
Discussion
The clinical trial described here represents the first
application of prospectively defined, adaptive decision-
making in a PAD trial. By addressing pre-trial uncer-
tainty in the maximum safe and well-tolerated dose, and
the goal of obtaining preliminary efficacy data from the
maximum tolerated dose, this approach allowed the
initial evaluation of a broad range of doses, followed by
the focusing of trial resources and human subjects on
the most promising treatment arms. The selection of
treatment arms to carry forward was based on safety
and tolerability endpoints, rather than the primary effi-
cacy outcome, reflecting the expectation that dose-limit-
ing side effects would appear quickly whereas evidence
of efficacy might not appear until the completion of
treatment.
If, instead of dropping the 25-mg K-134 treatment
arm, all arms had been continued to full enrollment,
then approximately 43 additional research subjects
would have been required to complete the trial (that is a
minimum of 85 subjects in all arms). This additional
enrollment would have increased the cost and duration
of the trial, and resulted in the exposure of additional
subjects to K-134, but without providing relevant addi-
tional information on either the safety or efficacy of K-
134 at doses likely to be clinically active.
Even when prospectively defined, adaptive clinical
trials are inherently more complex than traditional, par-
allel-armed designs because of the multiple ways the
clinical trial may “play out” when implemented. Thus, it
is often difficult or impossible to directly calculate the
power, type I error rate, or the expected accuracy in
dose selection for a particular trial design. Simulations
of the proposed trial design are often required to verify
acceptable operating and performance characteristics. In
practice, however, a general approach is to use simula-
tions to define the characteristics of a proposed design,
to adjust design parameters (e.g., thresholds for adding
or dropping arms, adjusting randomization proportions,
etc.) based on the simulation results, and then to repeat
the simulations. This iterative process is repeated until
the appropriate balance of trial size, power, and type I
error risk is obtained. In a learn-phase trial such as this
one, defining this appropriate balance is largely a subjec-
tive process. When an adaptive design is used in the
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numerical simulations are often quite extensive because
of the importance of precisely defining the trial’s operat-
ing characteristics under a wide range of null and alter-
native hypotheses. In the current setting, however, the
trial results were to be used to inform internal decision
making by the sponsor and, accordingly, the numerical
simulations were more limited.
The complexity of the adaptive design is also reflected
in the trial’s actual execution. While the original intent
was to conduct a formal assessment of the adaptive
design criteria after data from 50 patients had been
accrued through four weeks of treatment, in actuality
the review took place after many more patients had
been enrolled. This reflected an unanticipated accelera-
tion of enrollment, inherent delays in entering data into
and verifying data in the database, and the challenges of
scheduling meetings. Future trials can mitigate the risk
of delay by taking steps to better coordinate the start-up
of new sites and minimizing data entry delays. If serious
safety concerns exist, enrollment can be suspended
pending the adaptive decision making review. This step
was considered and felt unnecessary in the current trial.
Safety risks can be further minimized by ensuring
ongoing, unblinded review of all serious adverse events
as was done in the current trial.
The development of the adaptive design significantly
accelerated the clinical development of K-134. The
Steering Committee was faced with requiring a phase I
s t u d yi np a t i e n t sw i t hP A Dt od e f i n et h es a f e t ya n d
tolerability of K-134 and thus delaying development by
9-12 months, excluding the 100 mg arm from the phase
II trial and thus risk excluding the optimal dose, or con-
ducting a large phase II trial fully populating all five
study arms. The latter option would have resulted in
increased cost and time due to the additional enrollment
requirements as noted above. In practice the integration
of safety-specific assessments at early time points, the
use of the adaptive design, and an empowered and
experienced independent DMC allowed the trial to be
completed and subject safety optimized.
In addition to ultimately achieving efficiency in the
allocation of resources, the process of designing a pro-
spectively-defined adaptive trial requires and facilitates a
careful consideration of trial goals and the adequacy of
pre-trial information regarding the likely maximum tol-
erable dose, the effective dose range, and the treatment
effect. Similarly, the process of planning for an adaptive
interim analysis, which necessarily includes considera-
tions of data quality, availability, and other logistical
issues, may lead to better planning for the logistical sup-
port and conduct of the trial itself.
Conclusions
In this phase II, dose-finding trial of K-134 in the treat-
ment of stable intermittent claudication, no concerning
safety or tolerability signals were seen at interim analy-
sis, allowing the discontinuation of the lowest-dose-con-
taining arm and the retention of the two highest-dose-
containing arms.
Table 2 Safety and Tolerability Endpoints as of September 23, 2009*
Endpoint Trial Arm Observed Rate Model-based Rate (80% CI)
Placebo 0 of 57 (0%) 0.0 (—, —)
25 mg K-134 0 of 37 (0%) 0.0 (—, —)
Resting Tachycardia 50 mg K-134 0 of 52 (0%) 0.0 (—, —)
100 mg K-134 0 of 50 (0%) 0.0 (—, —)
Cilostazol 0 of 53 (Z%)
Placebo 0 of 43 (0%) 0.0 (—, —)
25 mg K-134 0 of 29 (0%) 0.0 (—, —)
Ischemic ECG Changes 50 mg K-134 0 of 45 (0%) 0.0 (—, —)
100 mg K-134 0 of 42 (0%) 0.0 (—, —)
Cilostazol 0 of 44 (Z%)
Placebo 2 of 63 (3%) 0.021 (0.008, 0.050)
25 mg K-134 41 of 42 (98%) **
Discontinuation 50 mg K-134 2 of 61 (3%) 0.055 (0.023, 0.13)
100 mg K-134 9 of 60 (15%) 0.14 (0.061, 0.28)
Cilostazol 5 of 57 (9%)
*See text for definitions of safety and tolerability endpoints.
**Nearly all patients discontinued due to arm dropping at previous analysis;
25 mg dose not included in logistic regression.
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